醫藥CDMO市場機會、成長要素、產業趨勢分析及2026-2035年預測

全球醫藥CDMO市場預計到2025年價值1,737億美元，年複合成長率為7.1%，到2035年將達到3,420億美元。

推動醫藥CDMO市場擴張的因素包括：成熟製藥公司和新興生物技術公司外包業務的增加、生物製藥需求的成長以及專業生產領域產能的限制。企業日益將資源集中在研發、商業化和市場拓展等核心職能，同時將生產營運外包給專業服務供應商。這一趨勢持續推動整個醫藥外包價值鏈的需求成長。與此同時，不斷變化的監管要求、日益提高的品質期望以及營運複雜性的增加，正在重塑競爭格局。複雜生產環境中的產能限制以及對專業生產技術的需求，進一步促進了市場成長。合約開發和生產組織（CDMO）也積極應對日益嚴格的法規環境，該環境更加重視品管、資料完整性、供應鏈透明度和合規標準。隨著醫藥產品線的日益複雜和多元化，CDMO在支持高效產品開發和商業化生產方面的作用在全球醫療保健市場中不斷擴大。

到2025年，契約製造服務市佔率將達到48.7%。此類別涵蓋了CDMO（合約研發產量機構）與製藥或生技公司之間簽訂的長期合約下所進行的大規模生產活動。該領域的領先地位反映了創新藥和成熟藥產品組合對外包生產模式日益成長的依賴。隨著製藥公司不斷最佳化營運效率並降低資本支出，契約製造服務仍然是產業成長的關鍵要素。預計在整個預測期內，外包生產業務在多個治療領域的擴張將繼續支撐對這些服務的需求。

預計到2025年，包裝和標籤服務市佔率將達到12.4%。該領域涵蓋初級和二級包裝服務、序列化解決方案、產品追蹤系統、臨床包裝服務以及特殊藥品包裝形式。隨著藥品供應鏈日益複雜，產品擴充性。隨著監管要求的不斷變化，對先進包裝和標籤技術的需求預計將持續成長。

預計到2025年，北美醫藥CDMO市場將佔據39.1%的佔有率。該地區的主導地位得益於眾多製藥和生物技術公司的集中、活躍的研發活動以及完善的契約製造基礎設施。對創新療法的持續投資、不斷拓展的藥物開發平臺以及強勁的商業化活動，都推動了對醫藥外包服務的持續需求。此外，該地區還受益於完善的法律規範、先進的生產能力以及對產能的持續投資，進一步鞏固了其在全球市場中的地位。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 行業洞察

• 產業生態系分析
• 影響產業的因素
  • 促進因素
    • 製藥和生技公司外包業務增加
    • 不斷擴充的生物製藥和先進療法產品線
    • 產能限制和對專用基礎設施的需求
    • 全球研發投入增加，藥物核准數量增加
  • 產業潛在風險與挑戰
    • 法規的複雜性和合規負擔
    • 價格壓力與競爭
  • 市場機遇
    • 下一代療法（CGT、mRNA、ADC）的推廣
    • 戰略合作夥伴關係和長期外包協議
• 成長潛力分析
• 技術與創新展望
  • 最新科技趨勢
  • 新興技術
• 價格趨勢分析
• 監理情勢
• 波特的分析
• PESTLE分析
• 未來市場趨勢
• 人工智慧和生成式人工智慧對市場的影響
• 投資與資金籌措分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
  • 北美洲
  • 歐洲
  • 亞太地區
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係和聯盟
  • 新產品發布
  • 業務拓展計劃

第5章 市場估計與預測：依服務業分類，2022-2035年

• 合約開發
• 契約製造
• 包裝和標籤
• 監管合規和品質服務
• 其他服務

第6章 市場估算與預測：依產品分類，2022-2035年

• API
  • 化學原料藥
  • 生物來源藥物成分
  • 高效API
• 成品藥製劑（FDF）
  • 固態劑型
  • 半固態製劑
  • 液體
  • 其他劑型

第7章 市場估計與預測：依藥物類型分類，2022-2035年

• 低分子
• 聚合物化合物

第8章 市場估計與預測：依治療領域分類，2022-2035年

• 腫瘤學
• 代謝/內分泌
• 心血管系統
• 中樞神經系統與精神醫學
• 感染疾病與疫苗
• 其他治療領域

第9章 市場估計與預測：依最終用途分類，2022-2035年

• 製藥公司
• 生技公司
• 其他最終用戶

第10章 市場估價與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • UAE

第11章：公司簡介

• Lonza Group
• Boehringer Ingelheim
• Thermo Fisher Scientific
• Catalent
• Samsung Biologics
• WuXi Biologics
• Recipharm
• Siegfried
• CordenPharma International
• Piramal Pharma Solutions
• Cambrex
• Fujifilm Diosynth Biotechnologies
• PCI Pharma
• Almac Group
• Abzena
• Syngene International

The Global Pharmaceutical CDMO Market was valued at USD 173.7 billion in 2025 and is estimated to grow at a CAGR of 7.1% to reach USD 342 billion by 2035.

Expansion of the Pharmaceutical CDMO Market is driven by rising outsourcing activities among both established pharmaceutical companies and emerging biotechnology firms, growing demand for biologics, and limited manufacturing capacity across specialized production segments. Organizations are increasingly focusing resources on core functions such as research, development, commercialization, and market expansion while delegating manufacturing operations to specialized service providers. This trend continues to strengthen demand across the pharmaceutical outsourcing value chain. At the same time, evolving regulatory requirements, increasing quality expectations, and growing operational complexity are reshaping the competitive landscape. Capacity limitations in advanced manufacturing environments and the need for specialized production expertise further support market growth. Contract development and manufacturing organizations are also navigating a more rigorous regulatory environment characterized by heightened emphasis on quality management, data integrity, supply chain visibility, and compliance standards. As pharmaceutical pipelines become more complex and diversified, the role of CDMOs in supporting efficient product development and commercial manufacturing continues to expand across global healthcare markets.

The contract manufacturing services segment held a 48.7% share in 2025. This category includes large-scale manufacturing activities conducted under long-term agreements between CDMOs and pharmaceutical or biotechnology companies. The segment's dominance reflects the increasing reliance on outsourced manufacturing models across both innovative and established drug portfolios. As pharmaceutical companies continue to optimize operational efficiency and reduce capital investment requirements, contract manufacturing services remain a critical component of industry growth. The expansion of outsourced production activities across multiple therapeutic categories is expected to support continued demand for these services throughout the forecast period.

The packaging and labeling services segment accounted for 12.4% share in 2025. This segment includes primary and secondary packaging operations, serialization solutions, product tracking systems, clinical packaging services, and specialized pharmaceutical packaging formats. The growing complexity of pharmaceutical supply chains and increasing regulatory requirements related to product traceability have elevated the importance of packaging and labeling services within the market. Pharmaceutical companies are increasingly seeking partners capable of delivering compliant, scalable, and efficient packaging solutions while ensuring product security and supply chain transparency. As regulatory expectations continue to evolve, demand for advanced packaging and labeling capabilities is expected to increase steadily.

North America Pharmaceutical CDMO Market held a 39.1% share in 2025. The region's leadership position is supported by a strong concentration of pharmaceutical and biotechnology companies, substantial research and development activity, and a well-established contract manufacturing infrastructure. Continued investment in innovative therapies, expanding drug development pipelines, and strong commercialization activity are contributing to sustained demand for outsourced pharmaceutical services. In addition, the region benefits from a highly developed regulatory framework, advanced manufacturing capabilities, and ongoing investments in production capacity, further strengthening its position within the global market.

Major companies operating in the Global Pharmaceutical CDMO Market include Thermo Fisher Scientific, Lonza Group AG, Samsung Biologics, Catalent, WuXi Biologics Co., Ltd., Boehringer Ingelheim, Recipharm, Piramal Pharma Solutions, Siegfried Holding, CordenPharma International, Cambrex, PCI Pharma Services, Fujifilm Diosynth Biotechnologies, Almac Group, Syngene International, and Abzena. Companies competing in the Pharmaceutical CDMO Market are implementing a range of strategic initiatives to strengthen their market presence and expand service capabilities. Capacity expansion remains a key focus, with organizations investing in new manufacturing facilities, advanced production technologies, and specialized infrastructure to meet growing customer demand. Many companies are increasing investments in biologics manufacturing, high-value therapeutic production, and advanced pharmaceutical technologies to address evolving industry requirements. Strategic acquisitions, partnerships, and long-term customer agreements are also being utilized to broaden service portfolios and enhance geographic reach.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Market estimates & forecasts parameters
• 1.8 Forecast model
  • 1.8.1 Quantified market impact analysis
    • 1.8.1.1 Mathematical impact of growth parameters on forecast
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
  • 2.1.1 Business trends
  • 2.1.2 Service trends
  • 2.1.3 Product trends
  • 2.1.4 Molecule type trends
  • 2.1.5 Therapeutic area trends
  • 2.1.6 End use trends
  • 2.1.7 Regional trends
• 2.2 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing outsourcing by pharmaceutical and biotech companies
    • 3.2.1.2 Growing biologics and advanced therapy pipeline
    • 3.2.1.3 Capacity constraints and need for specialized infrastructure
    • 3.2.1.4 Rising R&D investments and drug approvals globally
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Regulatory complexity and compliance burden
    • 3.2.2.2 Pricing pressure and competition
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of next-generation modalities (CGT, mRNA, ADCs)
    • 3.2.3.2 Strategic partnerships and long-term outsourcing contracts
• 3.3 Growth potential analysis
• 3.4 Technology and innovation landscape
  • 3.4.1 Current technological trends
  • 3.4.2 Emerging technologies
• 3.5 Pricing trend analysis (Driven by primary research)
• 3.6 Regulatory landscape (Driven by primary research)
  • 3.6.1 North America
  • 3.6.2 Europe
  • 3.6.3 Asia Pacific
  • 3.6.4 Latin America
  • 3.6.5 MEA
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends
• 3.10 Impact of AI and Generative AI on the market (Driven by primary research)
• 3.11 Investment & funding analysis (Driven by primary research)
• 3.12 Pharmaceutical CDMO total addressable market size, 2022 - 2035

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Service, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Contract development
• 5.3 Contract manufacturing
• 5.4 Packaging and labelling
• 5.5 Regulatory support & quality services
• 5.6 Other services

Chapter 6 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 API
  • 6.2.1 Chemical APIs
  • 6.2.2 Biological APIs
  • 6.2.3 High potency APIs
• 6.3 Finished drug formulations (FDF)
  • 6.3.1 Solid dose
  • 6.3.2 Semi solid dose
  • 6.3.3 Liquid
  • 6.3.4 Other dosage forms

Chapter 7 Market Estimates and Forecast, By Drug Type, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Small molecule
• 7.3 Large molecule

Chapter 8 Market Estimates and Forecast, By Therapeutic Area, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Oncology
• 8.3 Metabolic and endocrine
• 8.4 Cardiovascular
• 8.5 CNS and psychiatry
• 8.6 Infectious diseases and vaccines
• 8.7 Other therapeutic areas

Chapter 9 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Pharmaceutical companies
• 9.3 Biotechnology companies
• 9.4 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 France
  • 10.3.3 UK
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Lonza Group
• 11.2 Boehringer Ingelheim
• 11.3 Thermo Fisher Scientific
• 11.4 Catalent
• 11.5 Samsung Biologics
• 11.6 WuXi Biologics
• 11.7 Recipharm
• 11.8 Siegfried
• 11.9 CordenPharma International
• 11.10 Piramal Pharma Solutions
• 11.11 Cambrex
• 11.12 Fujifilm Diosynth Biotechnologies
• 11.13 PCI Pharma
• 11.14 Almac Group
• 11.15 Abzena
• 11.16 Syngene International